BioCryst Pharmaceuticals (BCRX) Earnings Date, Estimates & Call Transcripts $8.44 +0.09 (+1.09%) As of 10:38 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BioCryst Pharmaceuticals Earnings Summary BioCryst Pharmaceuticals announced Q2 2025 earnings on August 4, 2025, reporting an EPS of $0.15, which topped analysts' consensus estimates of $0.03 by $0.12. Quarterly revenue rose 49.5% year-over-year to $163.35 million, above analyst estimates of $149.59 million. With a trailing EPS of -$0.18, BioCryst Pharmaceuticals' earnings are expected to grow next year, from ($0.36) to ($0.07) per share. Latest Q2 Earnings DateAug. 4EstimatedConsensus EPS (Aug. 4) $0.03 Actual EPS (Aug. 4) $0.15 Beat By $0.12 Actual Revenue (Aug. 4) $163.35MQ2 2025 Earnings ResourcesQ2 2025 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Slide Deck Quarterly Report (10-Q)Slide DeckFull Screen Slide DeckPowered by Get BioCryst Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioCryst Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataBCRX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.BCRX Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. BioCryst Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateRevenue EstimateCompany Revenue GuidanceQ1 20251-$0.06-$0.06-$0.06Q2 20252$0.02$0.10$0.06Q3 20252$0.02$0.07$0.05Q4 20252$0.03$0.04$0.04 FY 2025 7 $0.01 $0.15 $0.08 Q1 20261$0.17$0.17$0.17Q2 20261$0.22$0.22$0.22Q3 20261$0.18$0.18$0.18Q4 20261$0.24$0.24$0.24 BioCryst Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails8/4/2025Q2 2025$0.03$0.15+$0.12$0.02$149.59M$163.35M2/24/2025Q4 2024-$0.07-$0.13 -$0.06-$0.13$126.64M$131.50M11/4/2024Q3 2024-$0.07-$0.07--$0.07$113.99M$117.10M8/5/2024Q2 2024-$0.17-$0.06+$0.11-$0.06$98.30M$109.30M5/6/2024Q1 2024-$0.23-$0.17+$0.06-$0.17$85.62M$92.80M2/26/2024Q4 2023-$0.24-$0.28 -$0.04-$0.25$89.19M$93.40M11/2/2023Q3 2023-$0.25-$0.19+$0.06-$0.19$86.54M$86.74M BioCryst Pharmaceuticals Earnings - Frequently Asked Questions When did BioCryst Pharmaceuticals announce their last quarterly earnings? BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earning data on Monday, August 4, 2025. Learn more on BCRX's earnings history. Did BioCryst Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, BioCryst Pharmaceuticals (NASDAQ:BCRX) reported $0.15 earnings per share (EPS) to beat the analysts' consensus estimate of $0.03 by $0.12. Learn more on analysts' earnings estimate vs. BCRX's actual earnings. How can I listen to BioCryst Pharmaceuticals' earnings conference call? The conference call for BioCryst Pharmaceuticals' latest earnings report can be listened to online. Listen to Conference Call How can I read BioCryst Pharmaceuticals' conference call transcript? The conference call transcript for BioCryst Pharmaceuticals' latest earnings report can be read online. Read Transcript How much revenue does BioCryst Pharmaceuticals generate each year? BioCryst Pharmaceuticals (NASDAQ:BCRX) has a recorded annual revenue of $450.71 million. How much profit does BioCryst Pharmaceuticals generate each year? BioCryst Pharmaceuticals (NASDAQ:BCRX) has a recorded net income of -$88.88 million. BCRX has generated -$0.18 earnings per share over the last four quarters. What is BioCryst Pharmaceuticals' price-to-earnings ratio? BioCryst Pharmaceuticals (NASDAQ:BCRX) has a . The price/earnings-to-growth ratio is 1.95. What is BioCryst Pharmaceuticals' EPS forecast for next year? BioCryst Pharmaceuticals' earnings are expected to grow from ($0.36) per share to ($0.07) per share in the next year. More Earnings Resources from MarketBeat Related Companies MDGL Earnings Date IONS Earnings Date RGEN Earnings Date ALKS Earnings Date LGND Earnings Date FOLD Earnings Date CLDX Earnings Date DVAX Earnings Date MNKD Earnings Date INVA Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Constellation Energy’s Earnings Beat Signals a New EraRealty Income Rallies Post-Earnings Miss—Here’s What Drove ItDon't Mix the Signal for Noise in Super Micro Computer's EarningsWhy Monolithic Power's Earnings and Guidance Ignited a RallyRivian Takes Earnings Hit—R2 Could Be the Stock's 2026 LifelinePalantir Stock Soars After Blowout Earnings ReportVertical Aerospace's New Deal and Earnings De-Risk Production This page (NASDAQ:BCRX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCryst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
